The Alkermes ALKS 3831 development program is part of our ongoing commitment to develop new therapeutic options for adults living with serious mental illness.
Respondents Reported Physical and Psychosocial Impacts of Living with Bipolar I Disorder and Side Effects of Medications Used to Treat the Disease More Than...